Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum MustGrow Biologics Corp V.MGRO

Alternate Symbol(s):  MGROF

MustGrow Biologics Corp. is a Canada-based agricultural biotechnology company. The Company is engaged in developing natural biological products derived from mustard seed to support sustainable farming. Its solutions provide alternatives to banned or restricted synthetic chemicals and fertilizers, promoting organic farming and soil health improvement. The Company develops mustard-based organic... see more

TSXV:MGRO - Post Discussion

MustGrow Biologics Corp > Fins on sedar
View:
Post by lscfa on May 08, 2023 4:34pm

Fins on sedar

Payments from partners were not disclosed in NRs.....

 

Deferred revenue
In August 2022, the Company and Sumitomo Corporation extended their Exclusive Evaluation and Option Agreement.  Pursuanttotheextensionagreement,MustGrowreceivedUSD500,000($641,200)whichhas been allocated to a future performance obligation and as such was recorded as deferred revenue.

 

In April 2022, the Company entered into an exclusive evaluation and option agreement with Janssen PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical companies of Johnson and Johnson. Pursuant to the agreement, MustGrow received EUR 200,000 ($272,500) which has been allocated to a future performance obligation and as such was recorded as deferred revenue.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities